Mutation detection in human estrogen receptor β gene in infertile male patients by denaturing high-performance liquid chromatography

سال انتشار: 1384
نوع سند: مقاله ژورنالی
زبان: انگلیسی
مشاهده: 391

فایل این مقاله در 5 صفحه با فرمت PDF قابل دریافت می باشد

این مقاله در بخشهای موضوعی زیر دسته بندی شده است:

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این مقاله:

شناسه ملی سند علمی:

JR_IJRM-3-1_002

تاریخ نمایه سازی: 16 شهریور 1395

چکیده مقاله:

Background: For screening sequence variations in genes, rapid turnover time is of fundamental importance. While, many of the current methods are unfortunately time consuming and technicallydifficult to implement. Denaturing high-performance liquid chromatography (DHPLC) method hadbeen shown to be a high-throughput, time saving, and economical tool for mutation screening. Objective: In the present study DHPLC method was used to explore the potential associationbetween estrogen receptor β gene (ESR2) variants and male infertility. Materials and Methods: DNA from 96 men with infertility and 96 normal male as control were screened for mutation in the nine exons of the ESR2 gene, using WAVE® DHPLC device equipped with a DNA separation column and automated sequence analysis on the ABI Prism 310.Results: DHPLC evaluation of ESR2 gene in 96 infertile patients, revealed one heterozygous sequence variation (IVS 8–4G>A) near the 5’ splicing region of intron 8 in 5 patients. No variation was identified in control population. Conclusion: Mutation detection by DHPLC, as it is presented in this context, is a high-throughput,quick, and economical tool for mutation screening. The gene alterations in ESR2 gene that we’ve found might increase susceptibility to infertility; but without cDNA screening, the consequences of these genetic alterations cannot be predicted.

کلیدواژه ها:

نویسندگان

Mir Davood Omrani

Assistant Professor, Urmia Medical Science University, Department of Cytogenetic & Molecular Medicine, Urmia,Iran.

Agneta Nordenskhold

Associated Professor, Karolinska University Hospital, Department of Molecular Medicine, Stockholm, Sweden.